STAAR Surgical Company
NASDAQ:STAAMedical - Instruments & Supplies
-$0.40 today
- Market cap
- $1.27B
- Beta
- 1.23
- P/E (TTM)
- -68.3
- EPS (TTM)
- -$0.42
Volume 0.45M
Average 1.07M
STAA Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
STAAR Surgical CompanyNASDAQ: STAA
Cost of Revenue · Q1 FY2026 · quarter ended Apr 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $26M rose 78.3% year over year, ahead of the -5.7% change in trailing-twelve-month cost of revenue. Sequentially, it rose 84.9% from the prior quarter. Over 3 fiscal years it compounded at -2.2% a year.
Context
- Cost of revenue amounted to 23.8% of revenue in FY2025, up 0.1 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +78.3% holds above the trailing-twelve-month pace of -5.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 57.02M USD
- Year-over-year change
- -23.3%
- 4-year CAGR
- +2.4%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-02 | 57.02M | -23.3% |
| FY2024 | 2024-12-27 | 74.32M | +6.5% |
| FY2023 | 2023-12-29 | 69.76M | +14.4% |
| FY2022 | 2022-12-30 | 61.01M | +17.7% |
| FY2021 | 2021-12-31 | 51.84M | — |
Cost of Revenue vs competitors
How STAA compares with its peers on the latest reported figures
- STAA's LTM Apr 2026 cost of revenue of $68.44M is the 4th highest of the 5 companies compared; the peer median is $1.91B.
- Its year-over-year change of -5.7% is the 4th highest of 5, against a peer median of +5.1%.
- Cost of revenue amounts to 23.6% of revenue for STAA, versus a peer median of 39.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $4.67B | +2.1% | +5.5% | 42.7% | |
| LTM Jun 2026 | $2.28B | +8.0% | +15.0% | 42.8% | |
| LTM Jul 2026 | $1.54B | +15.2% | +11.3% | 36.4% | |
| LTM Apr 2026 | $68.44M | -5.7% | -2.2% | 23.6% | |
| LTM Mar 2026 | $29.3M | -43.5% | +4.4% | 23.0% | |
| Peer median (excluding STAA) | $1.91B | +5.1% | +8.4% | 39.5% | |
Competitors are the stored peer set for STAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 230.47M | 284.39M | 322.42M | 313.9M | 239.44M |
| Cost of Revenue | 51.84M | 61.01M | 69.76M | 74.32M | 57.02M |
| Gross Profit | 178.64M | 223.38M | 252.65M | 239.58M | 182.42M |
| Gross Margin | 77.5% | 78.5% | 78.4% | 76.3% | 76.2% |
| Research & Development | 33.86M | 35.98M | 44.4M | 53.97M | 40.06M |
| Selling, General & Admin | 111.44M | 143.6M | 180.15M | 198.22M | 188.31M |
| Operating Expenses | 145.3M | 179.58M | 224.55M | 252.19M | 228.37M |
| Depreciation & Amortization | 3.64M | 4.51M | 5.12M | 6.89M | 8.73M |
| EBITDA | 34.98M | 50.06M | 38.82M | (2.16M) | (73.54M) |
| EBITDA Margin | 15.2% | 17.6% | 12.0% | -0.7% | -30.7% |
| Operating Income | 33.34M | 43.8M | 28.1M | (12.61M) | (45.95M) |
| Operating Margin | 14.5% | 15.4% | 8.7% | -4.0% | -19.2% |
| Interest Income | — | 2.45M | 6.99M | 5.91M | 4.59M |
| Interest Expense | 38K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (2.04M) | 1.75M | 5.6M | 3.56M | (36.32M) |
| Income Before Tax | 31.3M | 45.55M | 33.7M | (9.05M) | (82.26M) |
| Pre-Tax Margin | 13.6% | 16.0% | 10.5% | -2.9% | -34.4% |
| Income Tax Expense | 3.79M | 5.89M | 12.35M | 11.16M | (1.82M) |
| Net Income | 27.51M | 39.67M | 21.35M | (20.21M) | (80.45M) |
| Net Margin | 11.9% | 13.9% | 6.6% | -6.4% | -33.6% |
| EPS (Basic) | 0.52 | 0.83 | 0.44 | (0.41) | (1.62) |
| EPS (Diluted) | 0.50 | 0.80 | 0.43 | (0.41) | (1.62) |
| Weighted Avg Shares | 47.21M | 47.99M | 48.52M | 49.13M | 49.57M |
| Weighted Avg Shares (Diluted) | 49.46M | 49.38M | 49.43M | 49.13M | 49.57M |
STAAR Surgical Company
NASDAQ:STAA
Intrinsic Alpha fair value
Locked
Current Price
$25.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.